Date | Headline | |
---|---|---|
27-Nov-20 |
27-Nov-20
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
|
|
27-Nov-20 |
27-Nov-20
Actinogen Medical Annual General Meeting 27 Nov 2020: Audio only
|
|
27-Nov-20 |
27-Nov-20
Actinogen Medical Annual General Meeting: AGM Presentations
|
Date | Price Sensitive | Headline |
---|---|---|
18-Dec-14 | $ | ACW Board Changes |
18-Dec-14 | Appendix 3Z – Final Director’s Interest Notice | |
18-Dec-14 | Appendix 3X – Dr Bill Ketelbey | |
15-Dec-14 | Section 708A Notice | |
15-Dec-14 | Appendix 3B | |
15-Dec-14 | $ | ACW Appoints Dr Bill Ketelbey as CEO |
Date | Headline | |
---|---|---|
26-Oct-20 |
26-Oct-20
Annual Report to Shareholders Year Ended 30 Jun 2020
|
|
27-Aug-20 |
27-Aug-20
Appendix 4E & Annual Report 30 Jun 2020
|
|
29-Jul-20 |
29-Jul-20
Appendix 4C & Quarterly Report 30 Jun 2020
|
|
23-Apr-20 |
23-Apr-20
Appendix 4C & Quarterly Report 31 Mar 2020
|
2020 Annual General Meeting (AGM)
The 2020 Annual General Meeting was held at 10.30am AEDT on Friday, 27 November 2020 as a fully virtual online event.
Date | Analyst | Headline | |
---|---|---|---|
10-Dec-20 | Jonas Peculias |
10-Dec-20
Analyst: Jonas Peculias
Edison Healthcare Insight: Dec 2020Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 Dec 2020. This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research. |
|
12-Nov-20 | Jonas Peculias |
12-Nov-20
Analyst: Jonas Peculias
Edison Healthcare Insight: Nov 2020Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 6 Nov 2020. This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research. |
|
15-Oct-20 | Jonas Peculias |
15-Oct-20
Analyst: Jonas Peculias
Edison Healthcare Insight: Oct 2020Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 12 Oct 2020. This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research. Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way. Continue |
|
17-Sep-20 | Jonas Peculias |
17-Sep-20
Analyst: Jonas Peculias
Edison Healthcare Insight: Sep 2020Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 14 Sep 2020. This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research. Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way. Continue |
Date | Published By | Headline | |
---|---|---|---|
01-Dec-20 | Switzer Financial Group |
01-Dec-20
Published by: Switzer Financial Group
Switzer Small & Micro-Cap Virtual Investor Day (1 & 2 Dec 2020)
|
|
27-Nov-20 | Open Briefing |
27-Nov-20
Published by: Open Briefing
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
|
|
27-Nov-20 | Actinogen Medical |
27-Nov-20
Published by: Actinogen Medical
Actinogen Medical Annual General Meeting 27 Nov 2020: Audio only
|
|
20-Nov-20 | Biotech Daily |
20-Nov-20
Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
|
|
13-Nov-20 | Biotech Daily |
13-Nov-20
Published by: Biotech Daily
Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
|
Date | Published By | Headline | |
---|---|---|---|
27-Nov-20 | Open Briefing |
27-Nov-20
Published by: Open Briefing
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
|
|
20-Nov-20 | Biotech Daily |
20-Nov-20
Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
|
|
13-Nov-20 | Biotech Daily |
13-Nov-20
Published by: Biotech Daily
Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
|
|
09-Nov-20 | The Market Herald |
09-Nov-20
Published by: The Market Herald
Actinogen Medical (ASX:ACW) files new patent applications
|
|
09-Nov-20 | Melbourne Online News |
09-Nov-20
Published by: Melbourne Online News
Actinogen share price jumps 4.5% on patent news // Motley Fool Australia
|
Date | Published By | Headline | |
---|---|---|---|
27-Nov-20 | Open Briefing |
27-Nov-20
Published by: Open Briefing
Actinogen Medical Annual General Meeting 27 Nov 2020: Webcast presentation
|
|
09-Nov-20 | Finance News Network |
09-Nov-20
Published by: Finance News Network
Actinogen Medical (ASX:ACW) tackling Alzheimer’s by inhibiting excess cortisol production in the brain
|
|
03-Nov-20 | The Market Herald |
03-Nov-20
Published by: The Market Herald
Actinogen Medical (ASX:ACW) to test Fragile X syndrome treatment in Melbourne clinical trialWATCH FROM 4:50 to 13:33 |
|
02-Nov-20 | Boardroom Media |
02-Nov-20
Published by: Boardroom Media
ASX: ACW World first medical trial Fragile X Syndrome
|
|
29-Oct-20 | Monsoon Communications |
29-Oct-20
Published by: Monsoon Communications
Monsoon Morning Twilight Investor Briefing webinar video (28 Oct 2020) – watch from 17:50Dr Bill Ketelbey provided a clinical development update |
Date | Published By | Headline | |
---|---|---|---|
19-Nov-19 | Actinogen Medical |
19-Nov-19
Published by: Actinogen Medical
Investor Newsletter: Nov 2019
|
|
16-Apr-19 | Actinogen Medical |
16-Apr-19
Published by: Actinogen Medical
Investor Newsletter: Apr 2019
|
|
12-Dec-18 | Actinogen Medical |
12-Dec-18
Published by: Actinogen Medical
Investor Newsletter: Dec 2018
|
|
12-Oct-17 | Actinogen Medical |
12-Oct-17
Published by: Actinogen Medical
Investor Newsletter: October 2017
|
|
16-Mar-17 | Actinogen Medical |
16-Mar-17
Published by: Actinogen Medical
Quarterly Newsletter: Mar 2017
|
Date | Published By | Headline | |
---|---|---|---|
01-Dec-20 | Switzer Financial Group |
01-Dec-20
Published by: Switzer Financial Group
Switzer Small & Micro-Cap Virtual Investor Day (1 & 2 Dec 2020)
|
|
28-Oct-20 | Monsoon Communications |
28-Oct-20
Published by: Monsoon Communications
Morning Twilight Investor Briefing 11:00am to 11:40am
|
|
19-Oct-20 | Actinogen Medical |
19-Oct-20
Published by: Actinogen Medical
Actinogen Medical Conference Call (19 Oct 2020 at 11.00am AEDT)
|
|
08-Sep-20 | ASX |
08-Sep-20
Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020)
|
|
28-Jul-20 | Finance News Network |
28-Jul-20
Published by: Finance News Network
FNN CEO Showcase: Sydney (28 Jul 2020) Virtual Event
|
The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine from Edinburgh University, a company focused on the development of brain penetrant 11β-HSD1 enzyme inhibitors for the treatment of cognitive impairment. The lead drug in development by Corticrine was Xanamem. Corticrine received A$25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 (Xanamem) in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.
Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000
The share registry is managed by Link Market Services. To login and access your holding information, please go to: https://www.linkmarketservices.com.au
The share registry is managed by Link Market Services and shareholders can check their shareholdings by logging into https://www.linkmarketservices.com.au
All company shares are traded on the ASX and can be bought or sold through a licensed stock broker. The process of buying or selling shares is explained on the ASX website, please go to https://www.asx.com.au/products/shares/buying-selling-shares.htm
Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.
All annual reports are available on our website through this link – https://actinogen.com.au/investor-centre/#financial-reports
Current share prices are available on the ASX website www.asx.com.au and can be searched using the Company’s ASX ticker symbol: ACW. Our Investor Centre also includes the delayed share graph – https://actinogen.com.au/investor-centre/#share-price
The ASX ticker code for the Company is ASX:ACW
The latest financial reports can be found on our website at https://actinogen.com.au/investor-centre/#financial-reports
The Company’s end of financial year is the 30th of June
As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end. Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.
The Company’s auditors are Ernst and Young
K&L Gates
Peter Webse
Email: pwebse@governancecorp.com.au
Our Corporate Governance policy can be found on our website at: https://actinogen.com.au/investor-centre/#corporate-governance This includes our Board Charter, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Nomination Committee Charter, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Committee Charter, Risk Management and Internal Compliance and Control, the Securities Trading Policy and Shareholders Communication Policy.
The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses it against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.
ACW Anti-Bribery and Corruption Policy
ACW Audit Committee Charter
ACW Board Charter
ACW Code of Conduct
ACW Constitution
ACW Continuous Disclosure Policy
ACW Directors’ Skills Matrix
ACW Diversity Policy
ACW Nomination Committee Charter
ACW Performance Evaluation Practices
ACW Procedures for Selection and Appointment of Directors
ACW Remuneration Committee Charter
ACW Remuneration Policy
ACW Risk Management and Internal Compliance and Control
ACW Securities Trading Policy
ACW Shareholders Communication Policy
ACW Whistleblower Policy